Status
Conditions
Treatments
About
The SPRIMACC study is a prospective multicenter observational study with the primary endpoint to prospectively validate the Chole-Risk score in predicting a complicated postoperative course (post-operative major complications (Clavien-Dindo>=3a), length of stay (LOS) > 10 days or need of readmission within 30 days from the discharge) in patients undergoing Early Cholecystectomy (EC) for Acute Calculous Cholecystitis (ACC). The secondary endpoints of the study are to prospectively validate and compare other wellknown risk prediction models (the POSSUM/P-POSSUM score, the Modified Frailty Index (mFI), the Charlson Comorbidity Index (CCI), the American Society of Anesthesiologists (ASA) score and the APACHE II score) in predicting a complicated post-operative course in patients undergoing EC.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
have a diagnosis of Acute Calculous Cholecystitis (ACC) as defined by Tokyo Guidelines 2018 criteria
be candidate to Early Cholecystectomy (EC) during the index admission*
be ≥ 18 years old
be stratified for the risk of Common Bile Duct Stones (CBDS) according to the Israelian Score, and, in case of confirmation of CBDS receive pre-operative Endoscopic Retrograde Cholangiopancreatography (ERCP).
provide signed and dated informed consent form
willing to comply with all study procedures and be available for the duration of the study.
Exclusion criteria
pregnancy or lactation
acute cholecystitis not related to a gallstone etiology
onset of symptoms >10 days before cholecystectomy**
concomitant cholangitis or pancreatitis
intraoperative treatment of common bile duct stones
anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal